

Supporting Information

**Catalyst-Free Intramolecular Radical Cyclization Cascades initiated by direct
homolysis of C_{sp}³-Br under visible light**

**Panyi Huang,^a Zhiyang Yan,^a Jiaxin Ling,^a Peixuan Li,^a Jiayang Wang,^b
Jianjun Li,^a Bin Sun,^{*a} and Can Jin ^{*a}**

^a College of Pharmaceutical Sciences, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China; E-mail: jincan@zjut.edu.cn.

^b School of Life Sciences, Huzhou University, Huzhou, Zhejiang, PR China.

Table of Contents

General consideration.....	1
Experimental Procedure.....	2
1. Synthesis of substrates.....	2
2. Screening of Reaction Conditions.....	3
3. General procedure for the synthesis of product 2a	4
4. The Gram Scale Reaction.....	4
5. Mechanism investigation.....	5
6. X-ray structure of 2y	12
7. Characterization data for the products.....	13
8. References.....	31
9. ¹ H, ¹³ C and ¹⁹ F NMR spectra of the products and photocatalysts.....	32

General consideration

Unless otherwise specified, all reagents and solvents were obtained from commercial suppliers and used without further purification. The NMR spectra were recorded on a Bruker Avance 400 or 600 spectrometers at 400 MHz or 600MHz in CDCl_3 using tetramethylsilane as the internal standard. Chemical shifts (δ) are reported in ppm and coupling constants (J) in hertz (Hz). The following abbreviations were used to explain the multiplicities: s = singlet, d = doublet, dd = doublet of doublet, t = triplet, dt = doublet of triplet, td = triplet of doublet, q = quartet, m = multiplet, ddd = doublet of doublet of doublet. Melting points were determined using a Büchi B-540 capillary melting point apparatus. High-resolution mass spectra were obtained with a Bruker Impact II UHR-QTOF. by ESI on a TOF mass analyzer. Steady-state and time-resolved emission spectroscopy were determined using an Edinburgh FLS1000. Column chromatography was performed on silica gel (200–300 mesh).

The Material of the Irradiation Vessel

Manufacturer: Xi 'an WATTCAS experimental equipment co. LTD

Model: WP-TEC-1020HSL

Broadband source: $\lambda = 400\text{--}405\text{ nm}$

Material of the irradiation vessel: borosilicate reaction tube

Distance from the light source to the irradiation vessel: 2.0 cm

photon flux density: $5.044 \times 10^{-8}\text{ einstein s}^{-1}$

Not use any filters





Figure S1 (Photographed by author Panyi Huang)

Experimental Procedures


1. Synthesis of substrates

1.1 Synthesis of α -bromo- α,α -difluoroacetamides¹



General procedure: A 20 mL tube equipped with a magnetic stir bar was charged with lanthanum trifluoromethane sulfonate (0.25 mmol, 5.0 mol %). The tube was backfilled with argon, and then ethyl bromodifluoroacetate (6.0 mmol) and amine (5.0 mmol) were added. The mixture was stirred at room temperature and monitored by TLC. After the amine was exhausted, the mixture was purified by silica gel column chromatography to give the target amide.

1.2 Synthesis of diverse 3-difluorolactam substituted chroman-4-ones^{2,3}




General procedure: To a solution of salicylaldehyde or its derivatives **A** (0.016 mol, 1 equiv.) in dry MeCN (25 mL) was added K_2CO_3 (0.018 mol, 1.1 equiv.) and (*E*)-1,4-dibromo-2-butene (0.018 mol, 1.1 equiv.). The mixture was stirred under reflux for 4 hours and then poured into water (100 mL). The resulting mixture was extracted with DCM (3×50 mL). The combined organic layers were dried over Na_2SO_4 and concentrated under reduced pressure to obtain crude product **B**. The crude product **B** was purified by silica gel column chromatography with Petroleum ether/EtOAc to give the target product **B**.

To a stirred solution of 2-bromo-2,2-difluoro-*N*-phenylacetamide (3.92 mmol, 1.00 equiv.) in THF (25 mL) was added sodium hydride (4.31 mmol, 1.1 equiv.) at 0 °C. The mixture was stirred for 30 min and **B** (4.31 mmol, 1.10 equiv.) was added. The resulting mixture was stirred at 85 °C until the reaction was completed (monitored by TLC), which was then diluted with water and extracted three times with CH_2Cl_2 . The

combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure to obtain crude product **C**. The crude product **C** was purified by silica gel column chromatography with Petroleum ether/EtOAc to give the target product **C**.

2. Screening of Reaction Conditions

Table S1. Reaction optimization




entry	Light source	solvent	additive	yield (%) ^b
1 ^c	400-405 nm	DMSO	-	41
2	400-405 nm	DMSO	-	27
3	400-405 nm	DMSO	Na ₂ CO ₃	53
4	400-405 nm	DMSO	NaHCO ₃	57
5	400-405 nm	DMSO	NaOH	48
6	400-405nm	DMSO	TEA	73
7	400-405 nm	DMSO	DMAP	82
8	400-405nm	DMSO	DBU	80
9	400-405nm	DMF	DMAP	70
10	400-405nm	MeCN	DMAP	66
11	400-405nm	EtOAc	DMAP	trace
12	400-405nm	DCM	DMAP	trace
13	400-405nm	CHCl ₃	DMAP	21%
14	365-370 nm	DMSO	DMAP	68
15	380-385 nm	DMSO	DMAP	71
16	420-425 nm	DMSO	DMAP	75
17	450-455 nm	DMSO	DMAP	trace
18	Dark	DMSO	DMAP	N.D.
19 ^d	400-405nm	DMSO	DMAP	trace

^a Reaction conditions: **1a** (0.2 mmol), additive (0.3 mmol), solvent (2 mL), rt, 400 nm, 10 h. ^b Isolated yield. ^c Ir(ppy)₃ (5 mol%). ^d under air.


3. General procedure for the synthesis of products

3. 1 Synthesis of product 2a



General procedure: A mixture of 2-(allyloxy)aryl aldehyde derivatives **1a** (0.2 mmol), DMAP (0.3 mmol), and DMSO (2 mL) were added to a reaction tube. The tube was evacuated and backfilled with N₂ for three times. The mixture was then irradiated by 400–405 nm (10 w) for 10 h. After completion of the reaction, the resulting mixture was extracted with CH₂Cl₂ and the organic phase was then removed under vacuum. The residue was purified by column chromatography using a mixture of petroleum ether and ethyl acetate as eluent to give the desired product **2a**.


4. The Gram Scale Reaction



General procedure: A mixture of 2-(allyloxy)aryl aldehyde derivatives **1a** (5 mmol), DMAP (7.5 mmol), and DMSO (8 mL) were added to a 50 mL reaction tube. The tube was evacuated and backfilled with N₂ for three times. The mixture was then irradiated by 400–405 nm (10 w) for 24 h. After completion of the reaction, the resulting mixture was extracted with CH₂Cl₂. The organic phase was evaporated under vacuum. The residue was purified by column chromatography using a mixture of petroleum ether and ethyl acetate as eluent to give the desired product **2a** with a 79% yield.


5. Mechanism investigation

5.1 Thermal sensitive reaction



A mixture of 2-(allyloxy)aryl aldehyde derivatives **1a** (0.2 mmol), DMAP (0.3 mmol) and DMSO (2 mL) were added to a reaction tube. The tube was evacuated and backfilled with N₂ for three times. The reaction was carried out in dark conditions, and the corresponding product **2a** was not obtained even after heating at 50 °C for 10 hours.

5.2. C-X control Experiment



General procedure: A mixture of 2-(allyloxy)aryl aldehyde derivatives **1a** or **1ai-1aj** (0.2 mmol), DMAP (0.3 mmol), and DMSO (2 mL) were added to a reaction tube. The tube was evacuated and backfilled with N₂ for three times. The mixture was then irradiated by 400–405 nm (10 w) for 10 h. The resulting mixture was extracted with CH₂Cl₂ and the organic phase was then removed under vacuum. The residue was purified by column chromatography using a mixture of petroleum ether and ethyl acetate as eluent to give the desired product **2a**.

5.3 UV-visible absorption Spectra of 1a




Figure S2. Absorption spectra of 1a (dissolved in DMSO)

5.4 The electron paramagnetic resonance (EPR) experiments

To determine the species of radical involved in the present reaction, 5,5-dimethylpyrroline-*N*-oxide (DMPO) were employed. There was no signal when DMPO was added into DMSO solution of 2-(allyloxy)aryl aldehyde derivatives (**1a**) and DMAP without light irradiation (Figure S6a). Irradiation of the above solution under N₂ with blue LEDs (400-405 nm) resulted in the formation of a strong characteristic signal of alkyl radical with DMPO (Figure S6b), indicating the formation of fluoroalkyl radical in the reaction.






Figure S3. Electron spin resonance (ESR) spectra of DMPO with fluoroalkyl radical
 (a) A solution of DMPO (0.20 mol/L) with 2-(allyloxy)aryl aldehyde derivatives (**1a**) and DMAP in DMSO without light irradiation.
 (b) A solution of DMPO (0.20 mol/L) with 2-(allyloxy)aryl aldehyde derivatives (**1a**) and DMAP in DMSO under blue LEDs (400-405 nm) irradiation for 15min.

5.5 Radical trapped experiment using 1,1-diphenylethylene as a radical scavenger



A mixture of 2-(allyloxy)aryl aldehyde derivatives **1a** (0.2 mmol), DMAP (0.3 mmol) diphenylethylene (0.6 mmol) and DMSO (2 mL) were added to a reaction tube. The tube was evacuated and backfilled with N₂ for three times. The mixture was then irradiated by 400–405 nm (10 w) for 10 h. Only trace amounts of product **2a** was detected monitored by TLC.

5.6 Radical trapped experiment using TEMPO as a radical scavenger



A mixture of 2-(allyloxy)aryl aldehyde derivatives **1a** (0.2 mmol), DMAP (0.3 mmol) TEMPO (94 mg, 0.6 mmol) and DMSO (2 mL) were added to a reaction tube. The tube was evacuated and backfilled with N₂ for three times. The mixture was then irradiated by 400–405 nm (10 w) for 10 h. Subsequently, the reaction mixture was diluted with ethyl acetate (20 mL), transferred to a 60 mL separatory funnel, and washed with water. After evaporation of the solvent, the crude reaction mixture was then purified by column chromatography. The adduct **TEMPO-alkyl** was detected by NMR analysis.

¹H NMR (400 MHz, CDCl₃) δ 10.49 (s, 1H), 7.90 – 7.80 (m, 1H), 7.59 – 7.50 (m, 1H), 7.43 – 7.31 (m, 3H), 7.24 – 7.17 (m, 2H), 7.09 – 7.01 (m, 1H), 6.99 – 6.91 (m, 1H), 6.06 – 5.90 (m, 1H), 5.86 – 5.74 (m, 1H), 4.65 (d, *J* = 4.7 Hz, 2H), 4.37 (d, *J* = 6.1 Hz, 2H), 1.55 – 1.42 (m, 4H), 1.35 – 1.21 (m, 2H), 0.92 (d, *J* = 11.7 Hz, 10H). **¹³C NMR (101 MHz, CDCl₃)** δ 189.61, 160.72, 160.11 (C-F, ²*J*_{C-F}, *J* = 37.8 Hz), 140.25, 135.84, 129.27, 129.08, 129.03, 128.96, 128.45, 127.58, 125.08, 120.95, 116.66 (C-F, ¹*J*_{C-F}, *J* = 274.7 Hz), 112.89, 68.01, 60.91, 53.27, 40.17, 33.35, 21.02, 16.85. **¹⁹F NMR (376 MHz, CDCl₃)** δ -66.31.




Figure S4. ¹H NMR spectra of **TEMPO-alkyl**.




Figure S5. ^{13}C NMR spectra of TEMPO-alkyl.





Figure S6. ^{19}F NMR spectra of TEMPO-alkyl.

5.7 Bromine radical trapping experiment



A mixture of 2-(allyloxy)aryl aldehyde derivatives **1a** (0.6 mmol), DMAP (0.9 mmol) allylbenzene (0.25 ml) and DMSO (2 mL) were added to a reaction tube. The tube was evacuated and backfilled with N₂ for three times. The mixture was then irradiated by 400–405 nm (10 w) for 24 h. Subsequently, the mixture was diluted with water (20.0 mL) and extracted with DCM (3 x 15.0 mL). After evaporation of the solvent, the crude reaction mixture was then purified by column chromatography. The adduct **dibromide** was detected by NMR analysis. ¹H NMR (400 MHz, CDCl₃) δ 7.49 – 7.39 (m, 5H), 4.51 – 4.42 (m, 1H), 3.91 (dd, *J* = 10.5, 4.2 Hz, 1H), 3.73 (dd, *J* = 10.5, 8.9 Hz, 1H), 3.61 (dd, *J* = 14.5, 4.8 Hz, 1H), 3.24 (dd, *J* = 14.5, 7.8 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 136.99, 129.69, 128.70, 127.38, 52.70, 42.15, 36.39.




Figure S7. ¹H NMR spectra of **dibromide**.




Figure S8. ^{13}C NMR spectra of **dibromide**.

5.8 On/off experiments of 2a




Figure S9. On/off experiments of **2a**.

6. X-ray structure of 2y

CCDC: 2236364





Figure S10. Crystal data and details of data collection and refinement for compound 2y.

checkCIF/PLATON report

Structure factors have been supplied for datablock(s) exp_2605_auto

THIS REPORT IS FOR GUIDANCE ONLY. IF USED AS PART OF A REVIEW PROCEDURE FOR PUBLICATION, IT SHOULD NOT REPLACE THE EXPERTISE OF AN EXPERIENCED CRYSTALLOGRAPHIC REFEREE.

No syntax errors found. CIF dictionary Interpreting this report

Datablock: exp_2605_auto

Bond precision:	C-C = 0.0038 A	Wavelength=1.54184	
Cell:	a=17.1352 (4)	b=7.89497 (16)	c=14.2824 (4)
	alpha=90	beta=110.302 (3)	gamma=90
Temperature:	293 K		
	Calculated	Reported	
Volume	1812.12 (8)	1812.11 (8)	
Space group	P 21/c	P 1 21/c 1	
Hall group	-P 2ybc	-P 2ybc	
Moiety formula	C20 H14 F5 N O3	C20 H14 F5 N O3	
Sum formula	C20 H14 F5 N O3	C20 H14 F5 N O3	
Mr	411.32	411.32	
Dx, g cm ⁻³	1.508	1.508	
Z	4	4	
Mu (mm ⁻¹)	1.188	1.188	
F000	840.0	840.0	
F000'	843.51		
h, k, lmax	20, 9, 17	20, 9, 17	
Nref	3311	3278	
Tmin, Tmax	0.920, 0.942	0.091, 1.000	
Tmin'	0.920		

Correction method= # Reported T Limits: Tmin=0.091 Tmax=1.000
AbsCorr = MULTI-SCAN


Data completeness= 0.990 Theta (max)= 68.112

R(reflections)= 0.0662 (2582) wR2(reflections)=
0.1987 (3278)

S = 1.027 Npar= 290


7. Characterization Data for the Products

3,3-difluoro-4-(4-oxochroman-3-yl)-1-phenylpyrrolidin-2-one (2a)




The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (56 mg, 82%), m.p. 129.4–130.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.93 – 7.86 (m, 1H), 7.71 – 7.64 (m, 2H), 7.59 – 7.52 (m, 1H), 7.43 (s, 2H), 7.27 (s, 1H), 7.11 – 7.03 (m, 2H), 4.87 – 4.79 (m, 1H), 4.60 – 4.51 (m, 1H), 4.29 (t, *J* = 8.8 Hz, 1H), 3.90 (s, 1H), 3.29 – 3.20 (m, 1H), 3.02 – 2.86 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 191.96, 161.52, 161.16 (C-F, ²*J*_{C-F}, *J* = 30.3 Hz), 137.65, 136.77, 129.19, 127.30, 126.31, 121.92, 120.03, 119.98, 118.04, 117.42 (C-F, ¹*J*_{C-F}, *J* = 250.4 Hz), 68.48, 47.86, 43.88, 37.25 (C-F, ²*J*_{C-F}, *J* = 20.5 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -105.27, -105.98, -116.75, -117.46; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₉H₁₅F₂NNaO₃ 366.0912; Found 366.0898.

3,3-difluoro-4-(6-methyl-4-oxochroman-3-yl)-1-phenylpyrrolidin-2-one (2b)




The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (56 mg, 78%), m.p. 167.7–168.8 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.69 (d, *J* = 7.8 Hz, 3H), 7.44 (t, *J* = 8.0 Hz, 2H), 7.37 (dd, *J* = 8.5, 2.1 Hz, 1H), 7.27 (t, *J* = 7.4 Hz, 1H), 6.96 (d, *J* = 8.5 Hz, 1H), 4.83 – 4.77 (m, 1H), 4.57 – 4.51 (m, 1H), 4.26 (t, *J* = 9.6 Hz, 1H), 3.91 (t, *J* = 9.6 Hz, 1H), 3.24 – 3.18 (m, 1H), 3.04 – 2.86 (m, 1H), 2.34 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 192.15, 161.22 (C-F, ²*J*_{C-F}, *J* = 30.0 Hz), 159.63, 137.91, 137.66, 131.46, 129.20, 126.80, 126.33, 120.02, 119.61, 117.83, 117.33 (C-F, ¹*J*_{C-F}, *J* = 248.8 Hz), 68.49, 47.82, 43.90, 37.32 (C-F, ²*J*_{C-F}, *J* = 20.4 Hz), 20.43. ¹⁹F NMR (565 MHz, CDCl₃) δ -105.49, -105.96, -116.93, -117.41; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₁₇F₂NNaO₃ 380.1069; Found 380.1072.

3,3-difluoro-4-(6-methoxy-4-oxochroman-3-yl)-1-phenylpyrrolidin-2-one (2c)



The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (54 mg, 73%), m.p. 152.9–154.3 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.69 (d, *J* = 7.8 Hz, 2H), 7.44 (t, *J* = 8.0 Hz, 2H), 7.31 (d, *J* = 3.1 Hz, 1H), 7.28 (t, *J* = 6.1 Hz, 1H), 7.17 (dd, *J* = 9.0, 3.2 Hz, 1H), 7.00 (d, *J* = 9.0 Hz, 1H), 4.81 – 4.75 (m, 1H), 4.59 – 4.49 (m, 1H), 4.31 – 4.21 (m, 1H), 3.92 (t, *J* = 9.6 Hz, 1H), 3.83 (s, 3H), 3.25 – 3.18 (m, 1H), 3.03 – 2.88 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 192.01, 161.20 (C-F, ²*J*_{C-F}, *J* = 30.0 Hz), 156.31, 154.44, 137.65, 129.21, 126.34, 126.07, 120.00, 119.78, 119.38, 117.31 (C-F, ¹*J*_{C-F}, *J* = 249.6 Hz), 107.51, 68.63, 55.81, 47.78, 43.82, 37.31 (C-F, ²*J*_{C-F}, *J* = 20.4 Hz). ¹⁹F NMR (565 MHz, CDCl₃) δ -105.48, -105.95, -116.92, -117.40; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₁₇F₂NNaO₄ 396.1018; Found 396.1026.


3,3-difluoro-4-(6-fluoro-4-oxochroman-3-yl)-1-phenylpyrrolidin-2-one (2d)



The product was purified by column chromatography on silica gel (eluent: 10:1 petroleum ether: ethyl acetate) as a white solid (62 mg, 87%), m.p. 162.4–163.9 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.69 (d, *J* = 7.8 Hz, 2H), 7.56 – 7.52 (m, 1H), 7.45 (t, *J* = 8.0 Hz, 2H), 7.30 – 7.27 (m, 2H), 7.09 – 7.03 (m, 1H), 4.86 – 4.79 (m, 1H), 4.58 – 4.51 (m, 1H), 4.30 (t, *J* = 9.6 Hz, 1H), 3.90 (t, *J* = 9.6 Hz, 1H), 3.30 – 3.20 (m, 1H), 3.00 – 2.88 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 191.27 (C-F, ⁴*J*_{C-F}, *J* = 1.6 Hz), 161.05 (C-F, ²*J*_{C-F}, *J* = 29.8 Hz), 157.84 (C-F, ⁴*J*_{C-F}, *J* = 1.4 Hz), 157.44 (C-F, ¹*J*_{C-F}, *J* = 243.0 Hz), 137.59, 129.24, 126.41, 124.45 (C-F, ²*J*_{C-F}, *J* = 24.6 Hz), 120.40 (C-F, ³*J*_{C-F}, *J* = 6.6 Hz), 120.02, 119.83 (C-F, ³*J*_{C-F}, *J* = 7.4 Hz), 117.29 (C-F, ¹*J*_{C-F}, *J* = 249.4 Hz), 112.21 (C-F, ²*J*_{C-F}, *J* = 23.4 Hz), 68.71, 47.80 (C-F, ³*J*_{C-F}, *J* = 7.1 Hz), 43.75 (C-F, ³*J*_{C-F}, *J* = 4.7 Hz), 37.29 (C-F, ²*J*_{C-F}, *J* = 20.4 Hz). ¹⁹F NMR (565 MHz, CDCl₃) δ -105.43,


-105.91, -116.87, -117.34, -120.43; HRMS (ESI) m/z : $[M+Na]^+$ Calcd for $C_{19}H_{14}F_3NNaO_3$ 384.0818; Found 384.0801.

4-(6-chloro-4-oxochroman-3-yl)-3,3-difluoro-1-phenylpyrrolidin-2-one (2e)



The product was purified by column chromatography on silica gel (eluent: 10:1 petroleum ether: ethyl acetate) as a white solid (68 mg, 85%), m.p. 187.2–188.3 °C. 1H NMR (600 MHz, $CDCl_3$) δ 7.85 (d, $J = 2.5$ Hz, 1H), 7.68 (d, $J = 8.1$ Hz, 2H), 7.50 (dd, $J = 8.8, 2.5$ Hz, 1H), 7.45 (t, $J = 7.9$ Hz, 2H), 7.28 (t, $J = 8.4$ Hz, 1H), 7.03 (d, $J = 8.9$ Hz, 1H), 4.88 – 4.82 (m, 1H), 4.59 – 4.53 (m, 1H), 4.30 (t, $J = 9.4$ Hz, 1H), 3.89 (t, $J = 9.5$ Hz, 1H), 3.30 – 3.21 (m, 1H), 2.99 – 2.86 (m, 1H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 190.91, 161.01 (C-F, $^2J_{C-F}$, $J = 29.7$ Hz), 159.97, 137.56, 136.64, 129.25, 127.54, 126.60, 126.43, 120.78, 120.03, 119.81, 117.27 (C-F, $^1J_{C-F}$, $J = 249.3$ Hz), 68.64, 47.78 (C-F, $^3J_{C-F}$, $J = 7.0$ Hz), 43.69 (C-F, $^3J_{C-F}$, $J = 4.6$ Hz), 37.29 (C-F, $^3J_{C-F}$, $J = 20.5$ Hz). ^{19}F NMR (565 MHz, $CDCl_3$) δ -105.41, -105.89, -116.82, -117.29; HRMS (ESI) m/z : $[M+Na]^+$ Calcd for $C_{19}H_{14}ClF_2NNaO_3$ 400.0522; Found 400.0509.


4-(6-bromo-4-oxochroman-3-yl)-3,3-difluoro-1-phenylpyrrolidin-2-one (2f)



The product was purified by column chromatography on silica gel (eluent: 10:1 petroleum ether: ethyl acetate) as a white solid (64 mg, 80%), m.p. 199.2–200.3 °C. 1H NMR (600 MHz, $CDCl_3$) δ 8.03 – 7.99 (m, 1H), 7.68 (d, $J = 8.5$ Hz, 2H), 7.65 – 7.61 (m, 1H), 7.47 – 7.42 (m, 2H), 7.31 – 7.26 (m, 1H), 6.98 (d, $J = 8.8$ Hz, 1H), 4.86 (dd, $J = 11.8, 4.3$ Hz, 1H), 4.63 – 4.51 (m, 1H), 4.34 – 4.26 (m, 1H), 3.89 (t, $J = 9.6$ Hz, 1H), 3.32 – 3.15 (m, 1H), 3.00 – 2.86 (m, 1H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 190.76, 161.00 (C-F, $^2J_{C-F}$, $J = 29.4$ Hz), 160.41, 139.40, 137.56, 129.73, 129.25, 126.43, 121.26, 120.14, 120.03, 117.26 (C-F, $^1J_{C-F}$, $J = 249.4$ Hz), 114.63, 68.60, 47.77 (C-F, $^3J_{C-F}$, $J = 7.1$ Hz), 43.65 (C-F, $^3J_{C-F}$, $J = 4.6$ Hz), 37.29 (C-F, $^2J_{C-F}$, $J = 20.4$ Hz). ^{19}F NMR (565


MHz, CDCl₃) δ -105.42, -105.89, -116.81, -117.29; HRMS (ESI) m/z : [M+H]⁺ Calcd for C₁₉H₁₅BrF₂NO₃ 422.0198; Found 422.0204.

3,3-difluoro-4-(7-methyl-4-oxochroman-3-yl)-1-phenylpyrrolidin-2-one (2g)



The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (53 mg, 74%), m.p. 168.8–170.3 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.78 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 8.0 Hz, 2H), 7.44 (t, J = 8.0 Hz, 2H), 7.26 (t, J = 7.2 Hz, 1H), 6.90 (d, J = 8.1 Hz, 1H), 6.86 (s, 1H), 4.83 – 4.78 (m, 1H), 4.57 – 4.51 (m, 1H), 4.30 – 4.25 (m, 1H), 3.91 (t, J = 9.6 Hz, 1H), 3.24 – 3.18 (m, 1H), 2.99 – 2.88 (m, 1H), 2.40 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 191.59, 161.57, 161.22 (C-F, ² J_{C-F} , J = 29.9 Hz), 148.57, 137.66, 129.19, 127.18, 126.31, 123.36, 120.00, 117.97, 117.77, 117.41 (C-F, ¹ J_{C-F} , J = 249.5 Hz), 68.51, 47.85 (C-F, ³ J_{C-F} , J = 7.1 Hz), 43.77 (C-F, ³ J_{C-F} , J = 4.4 Hz), 37.36 (C-F, ² J_{C-F} , J = 20.4 Hz), 22.01. ¹⁹F NMR (565 MHz, CDCl₃) δ -105.47, -105.94, -116.93, -117.40; HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₂₀H₁₇F₂NNaO₃ 380.1069; Found 380.1055.


3,3-difluoro-4-(7-methoxy-4-oxochroman-3-yl)-1-phenylpyrrolidin-2-one (2h)



The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (52 mg, 70%), m.p. 155.3–156.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, J = 8.9 Hz, 1H), 7.69 (d, J = 7.7 Hz, 2H), 7.44 (t, J = 8.0 Hz, 2H), 7.27 (t, J = 7.6 Hz, 1H), 6.67 – 6.62 (m, 1H), 6.48 (d, J = 2.4 Hz, 1H), 4.84 – 4.78 (m, 1H), 4.61 – 4.53 (m, 1H), 4.31 – 4.23 (m, 1H), 3.93 (t, J = 10.5 Hz, 1H), 3.88 (s, 3H), 3.22 – 3.13 (m, 1H), 3.01 – 2.86 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 190.41, 166.65, 163.61, 161.27 (C-F, ² J_{C-F} , J = 29.8 Hz), 137.68, 129.20, 129.06, 126.32, 120.01, 117.47 (C-F, ¹ J_{C-F} , J = 249.3 Hz), 113.83, 110.88, 100.65, 68.83, 55.79, 47.86 (C-F, ³ J_{C-F} , J = 7.2 Hz), 43.45 (C-F, ³ J_{C-F} , J = 4.4 Hz), 37.43 (C-F,


$^2J_{C-F}$, $J = 20.4$ Hz). ^{19}F NMR (565 MHz, $CDCl_3$) δ -105.56, -106.03, -117.02, -117.49; HRMS (ESI) m/z : $[M+Na]^+$ Calcd for $C_{20}H_{17}F_2NNaO_4$ 396.1018; Found 396.1005.

3,3-difluoro-4-(7-fluoro-4-oxochroman-3-yl)-1-phenylpyrrolidin-2-one (2i)



The product was purified by column chromatography on silica gel (eluent: 10:1 petroleum ether: ethyl acetate) as a yellow solid (61 mg, 85%), m.p. 174.2–175.4 °C. 1H NMR (400 MHz, $CDCl_3$) δ 7.82 (dd, $J = 8.6, 6.7$ Hz, 1H), 7.58 (d, $J = 8.1$ Hz, 2H), 7.33 (t, $J = 7.9$ Hz, 2H), 7.20 – 7.14 (m, 1H), 6.75 – 6.68 (m, 1H), 6.67 – 6.56 (m, 1H), 4.76 (dd, $J = 11.7, 4.2$ Hz, 1H), 4.47 (dd, $J = 11.5, 9.5$ Hz, 1H), 4.20 (t, $J = 9.5$ Hz, 1H), 3.79 (t, $J = 9.6$ Hz, 1H), 2.24 – 2.06 (m, 1H), 2.89 – 2.75 (m, 1H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 190.53, 167.85 (C–F, $^1J_{C-F}$, $J = 257.9$ Hz), 163.22 (C–F, $^3J_{C-F}$, $J = 13.8$ Hz), 161.04 (C–F, $^2J_{C-F}$, $J = 29.7$ Hz), 137.60, 129.97 (C–F, $^3J_{C-F}$, $J = 11.5$ Hz), 129.22, 126.37, 119.99, 117.28 (C–F, $^1J_{C-F}$, $J = 249.5$ Hz), 116.99, 110.56 (C–F, $^2J_{C-F}$, $J = 22.9$ Hz), 104.86 (C–F, $^2J_{C-F}$, $J = 24.7$ Hz), 68.97, 47.84 (C–F, $^3J_{C-F}$, $J = 7.1$ Hz), 43.60 (C–F, $^3J_{C-F}$, $J = 4.5$ Hz), 37.31 (C–F, $^2J_{C-F}$, $J = 20.4$ Hz). ^{19}F NMR (565 MHz, $CDCl_3$) δ -98.65, -105.40, -105.87, -116.84, -117.31; HRMS (ESI) m/z : $[M+H]^+$ Calcd for $C_{19}H_{15}F_3NO_3$ 362.0999; Found 362.0995.


4-(7-chloro-4-oxochroman-3-yl)-3,3-difluoro-1-phenylpyrrolidin-2-one (2j)



The product was purified by column chromatography on silica gel (eluent: 10:1 petroleum ether: ethyl acetate) as a white solid (68 mg, 90%), m.p. 189.8–191.1 °C. 1H NMR (400 MHz, $CDCl_3$) δ 7.83 (d, $J = 8.3$ Hz, 1H), 7.68 (d, $J = 7.9$ Hz, 2H), 7.44 (t, $J = 7.7$ Hz, 2H), 7.30 – 7.23 (m, 1H), 7.12 – 7.02 (m, 2H), 4.92 – 4.81 (m, 1H), 4.62 – 4.51 (m, 1H), 4.31 (t, $J = 9.4$ Hz, 1H), 3.89 (t, $J = 9.4$ Hz, 1H), 3.32 – 3.21 (m, 1H), 3.03 – 2.81 (m, 1H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 190.94, 161.81, 161.01 (C–F, $^2J_{C-F}$, $J = 30.2$ Hz), 142.78, 137.59, 129.23, 128.55, 126.39, 122.82, 119.99, 118.60, 118.19, 117.25 (C–F, $^1J_{C-F}$, $J = 249.5$ Hz), 68.83, 47.86, 43.75, 37.31 (t, $J = 20.4$ Hz). ^{19}F NMR


(565 MHz, CDCl₃) δ -105.37, -105.85, -116.79, -117.27; HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₁₉H₁₄ClF₂NNaO₃ 400.0522; Found 400.0518.

4-(7-bromo-4-oxochroman-3-yl)-3,3-difluoro-1-phenylpyrrolidin-2-one (2k)



The product was purified by column chromatography on silica gel (eluent: 10:1 petroleum ether: ethyl acetate) as a white solid (70 mg, 83%), m.p. 202.7–204.1 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.75 (d, J = 8.4 Hz, 1H), 7.68 (d, J = 8.2 Hz, 2H), 7.44 (t, J = 7.8 Hz, 2H), 7.31 – 7.26 (m, 2H), 7.23 (d, J = 8.4 Hz, 1H), 4.89 – 4.83 (m, 1H), 4.62 – 4.52 (m, 1H), 4.31 (t, J = 9.4 Hz, 1H), 3.89 (t, J = 9.5 Hz, 1H), 3.31 – 3.20 (m, 1H), 3.01 – 2.83 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 191.12, 161.66, 161.01 (C-F, ² J_{C-F} , J = 29.4 Hz), 137.59, 131.37, 129.23, 128.51, 126.40, 125.68, 121.27, 120.01, 118.94, 117.23 (C-F, ¹ J_{C-F} , J = 249.5 Hz), 68.82, 47.86, 43.79, 37.33 (C-F, ³ J_{C-F} , J = 20.4 Hz). ¹⁹F NMR (565 MHz, CDCl₃) δ -105.37, -105.84, -116.79, -117.26; HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₁₉H₁₄BrF₂NNaO₃ 444.0017; Found 444.0014.


3,3-difluoro-4-(8-methyl-4-oxochroman-3-yl)-1-phenylpyrrolidin-2-one (2l)



The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (48 mg, 67%), m.p. 156.3–157.6 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.74 (d, J = 7.9 Hz, 1H), 7.72 – 7.67 (m, 2H), 7.47 – 7.39 (m, 3H), 7.31 – 7.24 (m, 1H), 7.04 – 6.92 (m, 1H), 4.94 – 4.83 (m, 1H), 4.62 – 4.51 (m, 1H), 4.35 – 4.27 (m, 1H), 3.92 – 3.84 (m, 1H), 3.30 – 3.20 (m, 1H), 3.07 – 2.88 (m, 1H), 2.29 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 192.38, 161.23 (C-F, ² J_{C-F} , J = 30.2 Hz), 159.79, 137.69, 137.58, 129.21, 127.46, 126.31, 124.85, 121.32, 119.99, 119.71, 117.46 (C-F, ¹ J_{C-F} , J = 249.2 Hz), 68.42, 47.89 (C-F, ³ J_{C-F} , J = 7.1 Hz), 43.73 (C-F, ³ J_{C-F} , J = 4.4 Hz), 37.29 (C-F, ² J_{C-F} , J = 20.4 Hz), 15.53. ¹⁹F NMR (565 MHz, CDCl₃) δ -105.37, -105.84, -116.82, -117.30; HRMS (ESI) m/z : [M+Na]⁺ Calcd for

C₂₀H₁₇F₂NNaO₃ 380.1069; Found 380.1057.


3,3-difluoro-4-(5-methyl-4-oxochroman-3-yl)-1-phenylpyrrolidin-2-one (2m)



The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (49 mg, 69%), m.p. 137.5–138.6 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, *J* = 7.7 Hz, 2H), 7.44 (t, *J* = 7.6 Hz, 2H), 7.38 (t, *J* = 7.6 Hz, 1H), 7.30 – 7.22 (dt, *J* = 8.4, 1.0 Hz, 1H), 6.91 (d, *J* = 8.1 Hz, 1H), 6.86 (d, *J* = 7.4 Hz, 1H), 4.84 – 4.75 (m, 1H), 4.54 – 4.46 (m, 1H), 4.31 (t, *J* = 9.5 Hz, 1H), 3.87 (t, 1H), 3.27 – 3.17 (m, 1H), 3.04 – 2.84 (m, 1H), 2.65 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 193.32, 162.51, 161.27 (C-F, ²*J*_{C-F}, *J* = 29.8 Hz), 142.37, 137.70, 135.37, 129.18, 126.31, 125.05, 120.07, 118.65, 117.52 (C-F, ¹*J*_{C-F}, *J* = 249.3 Hz), 115.95, 67.85, 48.03 (C-F, ³*J*_{C-F}, *J* = 7.3 Hz), 45.00 (C-F, ³*J*_{C-F}, *J* = 4.2 Hz), 37.44 (C-F, ²*J*_{C-F}, *J* = 20.3 Hz), 22.81. ¹⁹F NMR (376 MHz, CDCl₃) δ -105.29, -105.97, -116.82, -117.48; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₁₇F₂NNaO₃ 380.1069; Found 380.1054.


4-(5-chloro-4-oxochroman-3-yl)-3,3-difluoro-1-phenylpyrrolidin-2-one (2n)



The product was purified by column chromatography on silica gel (eluent: 10:1 petroleum ether: ethyl acetate) as a white solid (59 mg, 78%), m.p. 154.7–115.6 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.69 (d, *J* = 7.8 Hz, 2H), 7.45 – 7.37 (m, 3H), 7.26 (t, *J* = 7.4 Hz, 1H), 7.10 (d, *J* = 7.9 Hz, 1H), 6.99 (d, *J* = 8.4 Hz, 1H), 4.90 – 4.83 (m, 1H), 4.53 – 4.46 (m, 1H), 4.41 (*J* = 9.0 Hz, 1H), 3.90 – 3.81 (m, 1H), 3.37 – 3.27 (m, 1H), 3.04 – 2.82 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 190.26, 162.85, 161.02 (C-F, ²*J*_{C-F}, *J* = 30.9 Hz), 137.61, 135.48, 134.44, 129.21, 126.36, 125.08, 119.99, 117.44 (C-F, ¹*J*_{C-F}, *J* = 244.2 Hz), 117.39, 117.11, 68.08, 47.99 (C-F, ³*J*_{C-F}, *J* = 7.0 Hz), 44.72 (C-F, ³*J*_{C-F}, *J* = 4.4 Hz), 37.30 (C-F, ²*J*_{C-F}, *J* = 20.2 Hz). ¹⁹F NMR (565 MHz, CDCl₃) δ -


105.18, -105.65, -116.61, -117.08; HRMS (ESI) m/z : $[M+H]^+$ Calcd for $C_{19}H_{15}ClF_2NO_3$ 378.0703; Found 378.0697.

4-(6,8-di-tert-butyl-4-oxochroman-3-yl)-3,3-difluoro-1-phenylpyrrolidin-2-one (2o)



The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (57 mg, 63%), m.p. 214.3–215.9 °C. 1H NMR (600 MHz, DMSO) δ 7.70 (d, $J = 7.8$ Hz, 2H), 7.66 (d, $J = 2.4$ Hz, 1H), 7.56 (d, $J = 2.5$ Hz, 1H), 7.48 (t, $J = 8.0$ Hz, 2H), 7.29 (t, $J = 7.4$ Hz, 1H), 4.79 – 4.72 (m, 1H), 4.58 (t, $J = 10.7$ Hz, 1H), 4.17 (t, $J = 9.4$ Hz, 1H), 4.01 (t, $J = 8.3$ Hz, 1H), 3.46 – 3.40 (m, 1H), 3.29 – 3.22 (m, 1H), 1.39 (s, 9H), 1.28 (s, 9H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 192.90, 161.30 (C-F, $^2J_{C-F}$, $J = 29.7$ Hz), 158.67, 143.98, 138.69, 137.72, 131.59, 129.18, 126.28, 121.20, 120.01, 119.98, 117.41 (C-F, $^2J_{C-F}$, $J = 250.3$ Hz), 68.00, 47.88, 43.74, 37.43 (C-F, $^2J_{C-F}$, $J = 20.4$ Hz), 35.17, 34.54, 31.26, 29.66. ^{19}F NMR (565 MHz, DMSO) δ -102.10, -102.56, -114.22, -114.69; HRMS (ESI) m/z : $[M+Na]^+$ Calcd for $C_{27}H_{31}F_2NNaO_3$ 478.2164; Found 478.2154.


3,3-difluoro-4-(1-oxo-2,3-dihydro-1H-benzo[f]chromen-2-yl)-1-phenylpyrrolidin-2-one (2p)



The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (56mg, 71%), m.p. 176.7–177.9 °C. 1H NMR (600 MHz, $CDCl_3$) δ 9.39 (d, $J = 8.6$ Hz, 1H), 7.99 (d, $J = 9.0$ Hz, 1H), 7.80 (d, $J = 8.0$ Hz, 1H), 7.74 – 7.64 (m, 3H), 7.48 (t, $J = 7.4$ Hz, 1H), 7.43 (t, $J = 8.0$ Hz, 2H), 7.26 (d, $J = 7.4$ Hz, 1H), 7.17 (d, $J = 9.0$ Hz, 1H), 4.96 – 4.87 (m, 1H), 4.73 – 4.63 (m, 1H), 4.28 (t, $J = 9.4$ Hz, 1H), 3.94 (t, $J = 9.5$ Hz, 1H), 3.36 – 3.26 (m, 1H), 3.09 – 2.93 (m, 1H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 192.73, 163.73, 161.27 (C-F, $^2J_{C-F}$, $J = 29.7$


Hz), 138.34, 137.68, 131.37, 130.01, 129.33, 129.19, 128.72, 126.32, 125.43, 125.23, 120.05, 118.54, 117.48 (C-F, $^1J_{C-F}$, $J = 249.8$ Hz), 111.62, 68.39, 47.94 (C-F, $^3J_{C-F}$, $J = 7.2$ Hz), 44.51 (C-F, $^3J_{C-F}$, $J = 4.4$ Hz), 37.56 (C-F, $^2J_{C-F}$, $J = 20.2$ Hz). ^{19}F NMR (565 MHz, CDCl_3) δ -105.44, -105.91, -116.88, -117.35; HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{18}\text{F}_2\text{NO}_3$ 394.1249; Found 394.1243.

3,3-difluoro-4-(4-oxo-7-(thiophen-3-yl)chroman-3-yl)-1-phenylpyrrolidin-2-one (2q)



The product was purified by column chromatography on silica gel (eluent: 20:1 petroleum ether: ethyl acetate) as a white solid (63 mg, 74%), m.p. 153.8–154.4 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.11 (d, $J = 2.2$ Hz, 1H), 7.83 – 7.78 (m, 1H), 7.69 (d, $J = 7.9$ Hz, 2H), 7.48 – 7.41 (m, 4H), 7.40 – 7.37 (m, 1H), 7.28 (t, $J = 7.4$ Hz, 1H), 7.10 (d, $J = 8.6$ Hz, 1H), 4.91 – 4.81 (m, 1H), 4.65 – 4.55 (m, 1H), 4.30 (t, $J = 9.4$ Hz, 1H), 3.92 (t, $J = 9.5$ Hz, 1H), 3.33 – 3.24 (m, 1H), 3.07 – 2.89 (m, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 191.99, 161.14 (C-F, $^2J_{C-F}$, $J = 29.9$ Hz), 160.59, 140.43, 137.63, 134.89, 130.07, 129.23, 126.74, 126.37, 125.93, 124.43, 120.28, 120.01, 118.59, 117.30 (C-F, $^1J_{C-F}$, $J = 250.0$ Hz), 68.56, 47.84, 43.93, 37.32 (C-F, $^2J_{C-F}$, $J = 20.4$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -105.25, -105.96, -116.72, -117.43; HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{17}\text{F}_2\text{NNaO}_3\text{S}$ 448.0789; Found 448.0793.


1-acetyl-3-(4,4-difluoro-5-oxo-1-phenylpyrrolidin-3-yl)-2,3-dihydroquinolin-4(1H)-one (2r)



The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (53 mg, 69%), m.p. 180.7–181.3 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.03 (d, $J = 7.7$ Hz, 1H), 7.80 – 7.68 (m, 3H), 7.61 (t, $J =$


7.4 Hz, 1H), 7.45 (t, $J = 7.8$ Hz, 2H), 7.31 – 7.26 (m, 2H), 4.87 (d, $J = 11.9$ Hz, 1H), 4.47 (t, $J = 9.4$ Hz, 1H), 4.01 – 3.83 (m, 2H), 3.29 – 3.19 (m, 1H), 2.96 – 2.81 (m, 1H), 2.44 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 193.94, 169.48, 160.95 (C-F, $^2J_{\text{C-F}}$, $J = 31.7$ Hz), 143.71, 137.63, 134.91, 129.24, 127.83, 126.39, 125.36, 124.38, 124.12, 120.05, 117.52 (C-F, $^1J_{\text{C-F}}$, $J = 250.6$ Hz), 48.39, 47.69, 46.48, 38.60 (C-F, $^2J_{\text{C-F}}$, $J = 20.0$ Hz), 23.44. ^{19}F NMR (376 MHz, CDCl_3) δ -104.33, -105.04, -116.61, -117.32; HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{21}\text{H}_{18}\text{F}_2\text{N}_2\text{NaO}_3$ 407.1177; Found 407.1174

3,3-difluoro-1-(4-fluorophenyl)-4-(4-oxochroman-3-yl)pyrrolidin-2-one (2s)



The product was purified by column chromatography on silica gel (eluent: 10:1 petroleum ether: ethyl acetate) as a white solid (60 mg, 83%), m.p. 132.4–133.6 °C. ^1H NMR (600 MHz, DMSO) δ 7.79 (d, $J = 7.7$ Hz, 1H), 7.74 (dd, $J = 8.7, 4.8$ Hz, 2H), 7.62 (t, $J = 7.7$ Hz, 1H), 7.32 (t, $J = 8.1$ Hz, 2H), 7.11 (t, $J = 8.3$ Hz, 2H), 4.78 – 4.69 (m, 1H), 4.59 (t, $J = 11.0$ Hz, 1H), 4.18 (t, $J = 9.2$ Hz, 1H), 4.03 – 3.93 (m, 1H), 3.53 – 3.44 (m, 1H), 3.32 – 3.22 (m, 1H). ^{13}C NMR (151 MHz, DMSO) δ 192.05, 161.45, 161.37 (C-F, $^2J_{\text{C-F}}$, $J = 30.4$ Hz), 160.14 (C-F, $^1J_{\text{C-F}}$, $J = 243.6$ Hz), 136.98, 134.59 (C-F, $^4J_{\text{C-F}}$, $J = 2.6$ Hz), 127.24, 123.06 (C-F, $^3J_{\text{C-F}}$, $J = 8.3$ Hz), 122.09, 120.60, 118.74 (C-F, $^1J_{\text{C-F}}$, $J = 250.1$ Hz), 118.23, 116.31 (C-F, $^2J_{\text{C-F}}$, $J = 22.6$ Hz), 68.58, 47.96 (C-F, $^3J_{\text{C-F}}$, $J = 6.1$ Hz), 44.04 (C-F, $^3J_{\text{C-F}}$, $J = 4.0$ Hz), 36.14 (C-F, $^2J_{\text{C-F}}$, $J = 20.2$ Hz). ^{19}F NMR (565 MHz, DMSO) δ -102.00, -102.47, -114.06, -114.53, -115.65; HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{19}\text{H}_{14}\text{F}_3\text{NNaO}_3$ 384.0818; Found 384.0803.


1-(4-chlorophenyl)-3,3-difluoro-4-(4-oxochroman-3-yl)pyrrolidin-2-one (2t)



The product was purified by column chromatography on silica gel (eluent: 10:1


petroleum ether: ethyl acetate) as a white solid (65 mg, 86%), m.p. 136.2–137.5 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.90 (dd, *J* = 7.9, 1.7 Hz, 1H), 7.69 – 7.63 (m, 2H), 7.59 – 7.54 (m, 1H), 7.43 – 7.38 (m, 2H), 7.12 – 7.03 (m, 2H), 4.88 – 4.81 (m, 1H), 4.61 – 4.51 (m, 1H), 4.29 (t, *J* = 9.6 Hz, 1H), 3.88 (t, *J* = 9.6 Hz, 1H), 3.29 – 3.22 (m, 1H), 3.02 – 2.89 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 191.94, 161.53, 161.16 (C-F, ²*J*_{C-F}, *J* = 30.0 Hz), 136.86, 136.19, 131.66, 129.29, 127.32, 121.98, 121.08, 119.98, 118.07, 117.14 (C-F, ¹*J*_{C-F}, *J* = 249.3 Hz), 68.45, 47.79, 43.86, 37.24 (C-F, ²*J*_{C-F}, *J* = 20.4 Hz). ¹⁹F NMR (565 MHz, CDCl₃) δ -105.49, -105.96, -116.73, -117.21; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₁₅ClF₂NO₃ 378.0703; Found 378.0699.

1-(4-bromophenyl)-3,3-difluoro-4-(4-oxochroman-3-yl)pyrrolidin-2-one (2u)




The product was purified by column chromatography on silica gel (eluent: 10:1 petroleum ether: ethyl acetate) as a white solid (50 mg, 77%), m.p. 154.1–155.4 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.89 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.63 – 7.58 (m, 2H), 7.57 – 7.52 (m, 3H), 7.13 – 7.07 (m, 1H), 7.05 (d, *J* = 8.3 Hz, 1H), 4.83 (dd, *J* = 11.6, 4.2 Hz, 1H), 4.55 (dd, *J* = 11.7, 9.2 Hz, 1H), 4.32 – 4.24 (m, 1H), 3.87 (t, *J* = 9.6 Hz, 1H), 3.31 – 3.20 (m, 1H), 3.03 – 2.88 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 191.93, 161.53, 161.16 (C-F, ²*J*_{C-F}, *J* = 30.0 Hz), 136.86, 136.70, 132.24, 127.31, 121.98, 121.33, 119.98, 119.43, 118.07, 117.19 (C-F, ¹*J*_{C-F}, *J* = 249.4 Hz), 68.45, 47.72, 43.85, 37.21 (C-F, ²*J*_{C-F}, *J* = 20.4 Hz). ¹⁹F NMR (565 MHz, CDCl₃) δ -105.47, -105.94, -116.70, -117.18; HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₁₉H₁₅BrF₂NO₃ 422.0198; Found 422.0196.

3,3-difluoro-4-(4-oxochroman-3-yl)-1-(p-tolyl)pyrrolidin-2-one (2v)




The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (56 mg, 79%), m.p. 136.6–137.9 °C. ¹H NMR (600 MHz, DMSO) δ 7.79 (d, *J* = 7.3 Hz, 1H), 7.65 – 7.56 (m, 3H), 7.28 (d, *J* = 8.1 Hz, 2H), 7.15 – 7.09 (m, 2H), 4.73 (dd, *J* = 11.3, 4.4 Hz, 1H), 4.58 (t, *J* = 11.0 Hz, 1H), 4.18 (t, *J* = 9.3 Hz, 1H), 3.97 (t, *J* = 8.3 Hz, 1H), 3.56 – 3.44 (m, 1H), 3.31 – 3.21 (m, 1H), 2.32 (s, 3H). ¹³C NMR (151 MHz, DMSO) δ 192.08, 161.43, 161.18 (C-F, ²*J*_{C-F}, *J* = 30.9 Hz), 136.96, 135.85, 135.76, 129.95, 127.22, 122.08, 120.62, 120.60, 118.82 (C-F, ¹*J*_{C-F}, *J* = 249.7 Hz), 118.22, 68.58, 47.78 (C-F, ³*J*_{C-F}, *J* = 6.1 Hz), 44.03 (C-F, ³*J*_{C-F}, *J* = 4.0 Hz), 36.11 (C-F, ²*J*_{C-F}, *J* = 20.4 Hz), 20.97. ¹⁹F NMR (565 MHz, DMSO) δ -102.03, -102.49, -114.04, -114.50; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₁₇F₂NNaO₃ 380.1069; Found 380.1055.

3,3-difluoro-1-(4-methoxyphenyl)-4-(4-oxochroman-3-yl)pyrrolidin-2-one (2w)




The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (61 mg, 82%), m.p. 134.5–135.6 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.89 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.61 – 7.53 (m, 3H), 7.11 – 7.03 (m, 2H), 6.97 – 6.92 (m, 2H), 4.84 (dd, *J* = 11.6, 4.3 Hz, 1H), 4.56 (dd, *J* = 11.7, 9.0 Hz, 1H), 4.24 (t, *J* = 9.5 Hz, 1H), 3.87 (t, *J* = 9.6 Hz, 1H), 3.83 (s, 3H), 3.29 – 3.19 (m, 1H), 3.01 – 2.86 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 192.02, 161.54, 160.86 (C-F, ²*J*_{C-F}, *J* = 29.8 Hz), 157.76, 136.77, 130.72, 127.31, 121.92, 121.72, 120.03, 118.05, 117.50 (C-F, ¹*J*_{C-F}, *J* = 249.3 Hz), 114.34, 68.52, 55.51, 48.18 (C-F, ³*J*_{C-F}, *J* = 7.1 Hz), 43.91 (C-F, ³*J*_{C-F}, *J* = 4.5 Hz), 37.35 (C-F, ²*J*_{C-F}, *J* = 20.4 Hz). ¹⁹F NMR (565 MHz, CDCl₃) δ -105.28, -105.75, -116.66, -117.13; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₁₇F₂NNaO₄ 396.1018; Found 396.1006.

1-(3-chlorophenyl)-3,3-difluoro-4-(4-oxochroman-3-yl)pyrrolidin-2-one (2x)




The product was purified by column chromatography on silica gel (eluent: 10:1 petroleum ether: ethyl acetate) as a white solid (65 mg, 86%), m.p. 136.7–137.9 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.89 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.74 (t, *J* = 1.9 Hz, 1H), 7.62 (dd, *J* = 8.2, 1.4 Hz, 1H), 7.58 – 7.53 (m, 1H), 7.36 (t, *J* = 8.1 Hz, 1H), 7.24 (dd, *J* = 8.0, 1.1 Hz, 1H), 7.12 – 7.07 (m, 1H), 7.05 (d, *J* = 8.3 Hz, 1H), 4.84 (dd, *J* = 11.6, 4.2 Hz, 1H), 4.55 (dd, *J* = 11.7, 9.3 Hz, 1H), 4.33 – 4.27 (m, 1H), 3.87 (t, *J* = 9.6 Hz, 1H), 3.30 – 3.21 (m, 1H), 3.03 – 2.87 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 191.91, 161.53, 161.24 (C-F, ²*J*_{C-F}, *J* = 29.9 Hz), 138.72, 136.85, 135.02, 130.22, 127.32, 126.35, 121.98, 119.98, 118.05, 117.85, 117.14 (C-F, ¹*J*_{C-F}, *J* = 249.5 Hz), 68.45, 47.77, 43.85, 37.25 (C-F, ²*J*_{C-F}, *J* = 20.4 Hz). ¹⁹F NMR (565 MHz, CDCl₃) δ -105.53, -106.00, -116.77, -117.25; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₉H₁₄ClF₂NNaO₃ 400.0522; Found 400.0508.

3,3-difluoro-4-(4-oxochroman-3-yl)-1-(3-(trifluoromethyl)phenyl)pyrrolidin-2-one (2y)




The product was purified by column chromatography on silica gel (eluent: 10:1 petroleum ether: ethyl acetate) as a white solid (53 mg, 65%), m.p. 156.5–157.6 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.96 – 7.92 (m, 2H), 7.90 – 7.87 (m, 1H), 7.58 – 7.50 (m, 3H), 7.10 – 7.02 (m, 2H), 4.86 – 4.80 (m, 1H), 4.58 – 4.49 (m, 1H), 4.35 (t, *J* = 9.5 Hz, 1H), 3.92 (t, *J* = 9.5 Hz, 1H), 3.29 – 3.24 (m, 1H), 3.00 – 2.90 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 191.91, 161.52, 161.40 (C-F, ²*J*_{C-F}, *J* = 30.1 Hz), 138.19, 136.84, 131.66 (C-F, ²*J*_{C-F}, *J* = 32.8 Hz), 129.84, 127.27, 123.60 (C-F, ¹*J*_{C-F}, *J* = 272.6 Hz), 122.99, 122.79 (C-F, ³*J*_{C-F}, *J* = 3.6 Hz), 121.96, 119.97, 118.03, 117.07 (C-F, ¹*J*_{C-F}, *J* = 249.4 Hz), 116.51 (C-F, ³*J*_{C-F}, *J* = 3.8 Hz), 68.42, 47.74 (C-F, ³*J*_{C-F}, *J* = 7.1 Hz), 43.82 (C-F, ³*J*_{C-F}, *J* = 4.3 Hz), 37.26 (C-F, ³*J*_{C-F}, *J* = 20.4 Hz). ¹⁹F NMR (565 MHz, CDCl₃) δ -62.70, -105.56, -106.04, -116.80, -117.27; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₁₄F₅NNaO₃ 434.0786; Found 434.0773.

3,3-difluoro-4-(4-oxochroman-3-yl)-1-(m-tolyl)pyrrolidin-2-one (2z)



The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (55 mg, 77%), m.p. 139.7–140.9 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.90 (d, *J* = 7.3 Hz, 1H), 7.56 (t, *J* = 7.2 Hz, 1H), 7.48 (s, 2H), 7.31 (t, *J* = 8.1 Hz, 1H), 7.11 – 7.03 (m, 3H), 4.89 – 4.80 (m, 1H), 4.59 – 4.53 (m, 1H), 4.28 (t, *J* = 9.4 Hz, 1H), 3.89 (t, *J* = 9.4 Hz, 1H), 3.30 – 3.21 (m, 1H), 3.01 – 2.87 (m, 1H), 2.40 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 192.02, 161.55, 161.11 (C-F, ²*J*_{C-F}, *J* = 31.7 Hz), 139.22, 137.59, 136.77, 129.00, 127.30, 127.15, 121.92, 120.63, 120.03, 118.05, 117.38 (C-F, ¹*J*_{C-F}, *J* = 250.2 Hz), 117.21, 68.51, 47.96, 43.91, 37.31 (C-F, ²*J*_{C-F}, *J* = 20.4 Hz), 21.54. ¹⁹F NMR (565 MHz, CDCl₃) δ -105.35, -105.82, -116.90, -117.37; HRMS (ESI) *m/z*: [M+Na]⁺ C₂₀H₁₇F₂NNaO₃ 380.1069; Found 380.1056.


3,3-difluoro-1-(3-methoxyphenyl)-4-(4-oxochroman-3-yl)pyrrolidin-2-one (2aa)



The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (54 mg, 72%), m.p. 152.3–153.7 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.88 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.58 – 7.52 (m, 1H), 7.39 (t, *J* = 2.2 Hz, 1H), 7.31 (t, *J* = 8.2 Hz, 1H), 7.16 (dd, *J* = 8.1, 1.5 Hz, 1H), 7.09 – 7.06 (m, 1H), 7.04 (d, *J* = 8.3 Hz, 1H), 6.80 (dd, *J* = 8.2, 2.2 Hz, 1H), 4.82 (dd, *J* = 11.6, 4.3 Hz, 1H), 4.54 (dd, *J* = 11.7, 9.2 Hz, 1H), 4.31 – 4.24 (m, 1H), 3.91 – 3.84 (m, 1H), 3.83 (s, 3H), 3.28 – 3.20 (m, 1H), 3.01 – 2.83 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 191.93, 161.51, 161.20 (C-F, ²*J*_{C-F}, *J* = 29.8 Hz), 160.14, 138.80, 136.76, 129.89, 127.31, 121.92, 120.02, 118.03, 117.35 (C-F, ¹*J*_{C-F}, *J* = 249.4 Hz), 112.08, 111.89, 106.08,


68.49, 55.44, 47.97, 43.88, 37.21 (C-F, $^2J_{C-F}$, $J = 20.4$ Hz). ^{19}F NMR (565 MHz, CDCl_3) δ -105.35, -105.82, -116.79, -117.27; HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{20}\text{H}_{17}\text{F}_2\text{NNaO}_4$ 396.1018; Found 396.1000.

3,3-difluoro-4-(4-oxochroman-3-yl)-1-(o-tolyl)pyrrolidin-2-one (2ab)



The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (41 mg, 58%), m.p. 143.2–144.6 °C. ^1H NMR (600 MHz, CDCl_3) δ 7.75 (d, $J = 7.8$ Hz, 1H), 7.69 (d, $J = 8.4$ Hz, 2H), 7.49 – 7.38 (m, 3H), 7.26 (d, $J = 7.3$ Hz, 1H), 6.98 (t, $J = 7.6$ Hz, 1H), 4.88 (dd, $J = 11.6, 4.3$ Hz, 1H), 4.57 (dd, $J = 11.6, 9.4$ Hz, 1H), 4.37 – 4.28 (m, 1H), 3.90 (t, $J = 9.6$ Hz, 1H), 3.29 – 3.21 (m, 1H), 3.03 – 2.88 (m, 1H), 2.29 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 192.38, 161.23 (C-F, $^2J_{C-F}$, $J = 29.8$ Hz), 159.78, 137.66, 137.58, 129.21, 127.46, 126.33, 124.85, 121.32, 120.01, 119.69, 117.38 (C-F, $^1J_{C-F}$, $J = 249.2$ Hz), 68.42, 47.92, 43.75, 37.33 (C-F, $^2J_{C-F}$, $J = 20.3$ Hz), 15.53. ^{19}F NMR (565 MHz, CDCl_3) δ -105.42, -105.90, -116.87, -117.34; HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{20}\text{H}_{17}\text{F}_2\text{NNaO}_3$ 380.1069; Found 380.1054.


1-(3,4-dimethylphenyl)-3,3-difluoro-4-(4-oxochroman-3-yl)pyrrolidin-2-one (2ac)



The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (52 mg, 70%), m.p. 146.9–148.3 °C. ^1H NMR (600 MHz, CDCl_3) δ 7.90 (dd, $J = 7.9, 1.7$ Hz, 1H), 7.58 – 7.54 (m, 1H), 7.44 (d, $J = 2.2$ Hz, 1H), 7.39 (dd, $J = 8.2, 2.4$ Hz, 1H), 7.17 (d, $J = 8.2$ Hz, 1H), 7.11 – 7.07 (m, 1H), 7.06 (d, $J = 8.4$ Hz, 1H), 4.84 (dd, $J = 11.5, 4.3$ Hz, 1H), 4.56 (dd, $J = 11.7, 9.1$ Hz, 1H), 4.28 – 4.22 (m, 1H), 3.91 – 3.81 (m, 1H), 3.31 – 3.20 (m, 1H), 3.03 – 2.86


(m, 1H), 2.30 (s, 3H), 2.27 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 192.07, 161.55, 160.97 (C-F, $^2J_{\text{C-F}}$, $J = 29.6$ Hz), 137.61, 136.77, 135.37, 134.99, 130.15, 127.30, 121.92, 121.24, 120.04, 118.06, 117.60, 117.49 (C-F, $^1J_{\text{C-F}}$, $J = 249.2$ Hz), 68.53, 48.00 (C-F, $^3J_{\text{C-F}}$, $J = 7.1$ Hz), 43.93 (C-F, $^3J_{\text{C-F}}$, $J = 4.5$ Hz), 37.33 (C-F, $^2J_{\text{C-F}}$, $J = 20.4$ Hz), 19.98, 19.31. ^{19}F NMR (565 MHz, CDCl_3) δ -105.31, -105.78, -116.81, -117.29; HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{21}\text{H}_{19}\text{F}_2\text{NNaO}_3$ 394.1225; Found 394.1214.

1-(3,4-dichlorophenyl)-3,3-difluoro-4-(4-oxochroman-3-yl)pyrrolidin-2-one (2ad)



The product was purified by column chromatography on silica gel (eluent: 10:1 petroleum ether: ethyl acetate) as a white solid (72 mg, 88%), m.p. 162.4–163.6 °C. ^1H NMR (600 MHz, DMSO) δ 8.03 (d, $J = 2.1$ Hz, 1H), 7.80 – 7.77 (m, 1H), 7.75 – 7.70 (m, 2H), 7.64 – 7.59 (m, 1H), 7.13 – 7.09 (m, 2H), 4.73 (dd, $J = 11.4, 4.7$ Hz, 1H), 4.60 (t, $J = 11.1$ Hz, 1H), 4.21 (t, $J = 9.4$ Hz, 1H), 4.06 – 3.99 (m, 1H), 3.54 – 3.47 (m, 1H), 3.33 – 3.21 (m, 1H). ^{13}C NMR (151 MHz, DMSO) δ 191.97, 161.80 (C-F, $^2J_{\text{C-F}}$, $J = 30.7$ Hz), 161.43, 138.06, 137.00, 131.94, 131.41, 128.37, 127.21, 122.18, 122.07, 120.69, 120.55, 118.48 (C-F, $^1J_{\text{C-F}}$, $J = 251.5$ Hz), 118.21, 68.54, 47.52, 44.13, 35.91 (C-F, $^2J_{\text{C-F}}$, $J = 20.2$ Hz). ^{19}F NMR (565 MHz, DMSO) δ -101.53, -102.00, -113.92, -114.39; HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{19}\text{H}_{13}\text{Cl}_2\text{F}_2\text{NNaO}_3$ 434.0133; Found 434.0130.


1-(3-chloro-5-methylphenyl)-3,3-difluoro-4-(4-oxochroman-3-yl)pyrrolidin-2-one (2ae)



The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (62 mg, 79%), m.p. 154.1–155.4 °C. ^1H


NMR (600 MHz, CDCl₃) δ 7.90 (dd, $J = 7.8, 1.3$ Hz, 1H), 7.61 – 7.51 (m, 2H), 7.41 (s, 1H), 7.15 – 7.00 (m, 3H), 4.84 (dd, $J = 11.6, 4.1$ Hz, 1H), 4.55 (dd, $J = 11.6, 9.3$ Hz, 1H), 4.28 (t, $J = 9.4$ Hz, 1H), 3.86 (t, $J = 9.5$ Hz, 1H), 3.34 – 3.18 (m, 1H), 3.00 – 2.84 (m, 1H), 2.38 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 191.97, 161.54, 161.19 (C-F, ² J_{C-F} , $J = 29.9$ Hz), 140.76, 138.48, 136.85, 134.64, 127.31, 127.05, 121.98, 119.99, 118.60, 118.06, 117.21, 117.12 (C-F, ³ J_{C-F} , $J = 249.4$ Hz), 68.46, 47.84 (C-F, ³ J_{C-F} , $J = 7.1$ Hz), 43.85 (C-F, ³ J_{C-F} , $J = 4.4$ Hz), 37.25 (C-F, ² J_{C-F} , $J = 20.4$ Hz), 21.42. ¹⁹F NMR (565 MHz, CDCl₃) δ -105.48, -105.95, -116.81, -117.29; HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₂₀H₁₆ClF₂NNaO₃ 414.0679; Found 414.0674.

3,3-difluoro-4-(4-oxochroman-3-yl)-1-(4-phenylbutyl)pyrrolidin-2-one (2af)




The product was purified by column chromatography on silica gel (eluent: 20:1 petroleum ether: ethyl acetate) as a white solid (66 mg, 83%), m.p. 140.5–141.3 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.88 (d, $J = 7.1$ Hz, 1H), 7.56 (t, $J = 7.2$ Hz, 1H), 7.28 (d, $J = 6.4$ Hz, 2H), 7.18 (t, $J = 6.9$ Hz, 3H), 7.11 – 7.02 (m, 2H), 4.83 – 4.73 (m, 1H), 4.56 – 4.47 (m, 1H), 3.73 (t, $J = 9.3$ Hz, 1H), 3.49 – 3.30 (m, 3H), 3.19 – 3.09 (m, 1H), 2.86 – 2.71 (m, 1H), 2.66 (t, $J = 6.0$ Hz, 2H), 1.68 – 1.59 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 192.09, 162.43 (C-F, ² J_{C-F} , $J = 29.8$ Hz), 161.54, 141.65, 136.72, 128.42, 128.41, 127.29, 125.95, 121.87, 120.05, 118.05, 117.74 (C-F, ¹ J_{C-F} , $J = 251.1$ Hz), 68.55, 46.72, 43.91, 43.27, 37.66 (C-F, ² J_{C-F} , $J = 20.6$ Hz), 35.23, 28.24, 26.13. ¹⁹F NMR (376 MHz, CDCl₃) δ -106.61, -107.32, -116.59, -117.30. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₂₃H₂₃F₂NNaO₃ 422.1538; Found 422.1534.

3,3-difluoro-1-(furan-2-ylmethyl)-4-(4-oxochroman-3-yl)pyrrolidin-2-one (2ag)



The product was purified by column chromatography on silica gel (eluent: 20:1 petroleum ether: ethyl acetate) as a white solid (55 mg, 79%), m.p. 121.7–122.8 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, *J* = 7.9 Hz, 1H), 7.54 (t, *J* = 8.5 Hz, 1H), 7.40 (s, 1H), 7.11 – 7.00 (m, 2H), 6.40 – 6.29 (m, 2H), 4.82 – 4.74 (m, 1H), 4.55 (s, 2H), 4.52 – 4.45 (m, 1H), 3.82 (t, *J* = 9.5 Hz, 1H), 3.40 (t, *J* = 8.9 Hz, 1H), 3.18 – 3.07 (m, 1H), 2.87 – 2.71 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 191.99, 162.12 (C-F, ²*J*_{C-F}, *J* = 29.5 Hz), 161.50, 147.77, 143.22, 136.69, 127.27, 121.86, 120.02, 118.02, 117.57 (C-F, ¹*J*_{C-F}, *J* = 251.5 Hz), 110.61, 109.72, 68.53, 46.62, 43.91, 39.96, 37.62 (C-F, ²*J*_{C-F}, *J* = 20.7 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -106.54, -107.25, -116.58, -117.29. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₈H₁₅F₂NNaO₄ 370.0861; Found 370.0858.

3-fluoro-4-(4-oxochroman-3-yl)-1-phenylpyrrolidin-2-one (2ah)




The product was purified by column chromatography on silica gel (eluent: 15:1 petroleum ether: ethyl acetate) as a white solid (56 mg, 86%), m.p. 121.4–122.7 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.91 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.66 (dd, *J* = 8.6, 0.9 Hz, 2H), 7.58 – 7.53 (m, 1H), 7.44 – 7.37 (m, 2H), 7.25 – 7.20 (m, 1H), 7.11 – 7.07 (m, 1H), 7.05 (d, *J* = 8.4 Hz, 1H), 5.20 (dd, *J* = 52.9, 9.3 Hz, 1H), 4.79 – 4.72 (m, 1H), 4.57 – 4.48 (m, 1H), 4.25 (dd, *J* = 10.2, 8.7 Hz, 1H), 3.77 – 3.70 (m, 1H), 3.11 – 3.03 (m, 1H), 2.93 – 2.78 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 192.26, 166.75 (C-F, ²*J*_{C-F}, *J* = 21.4 Hz), 161.55, 138.20, 136.66, 129.05, 127.32, 125.60, 121.92, 120.25, 119.82, 118.01, 91.88 (C-F, ¹*J*_{C-F}, *J* = 191.3 Hz), 69.26, 47.94, 47.84 (C-F, ³*J*_{C-F}, *J* = 7.1 Hz), 37.54 (C-F, ²*J*_{C-F}, *J* = 18.1 Hz). ¹⁹F NMR (565 MHz, CDCl₃) δ -187.83; HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₉H₁₆FNNaO₃ 348.1006; Found 348.0995.


8. References

1. Wang, L.; Wei, X. J.; Jia, W. L.; Zhong, J. J.; Wu, L. Z.; Liu, Q. *Org. Lett.* **2014**, *16*, 5842-5845.
2. Gualandi, A.; Rodeghiero, G.; Faraone, A.; Patuzzo, F.; Marchini, M.; Calogero, F.; Perciaccante, R.; Jansen, P. T.; Ceroni, P.; Cozzi, P. G. *Chem. Commun.* **2019**, *55*, 6838-6841.
3. Johannes, K.; Lukasz, W.; Nicolai, C. *Angew. Chemie.* **2022**, doi: 10.1002/anie.202202306.

8 ^1H , ^{13}C and ^{19}F NMR spectra of products




^1H NMR (CDCl_3 , 400MHz)




^1H NMR Spectrum of Compound 2a




^{13}C NMR (CDCl_3 , 101MHz)




^{13}C NMR Spectrum of Compound 2a




¹⁹F NMR Spectrum of Compound 2a




¹H NMR Spectrum of Compound 2b




¹³C NMR Spectrum of Compound 2b




¹⁹F NMR Spectrum of Compound 2b




¹H NMR Spectrum of Compound 2c




¹³C NMR Spectrum of Compound 2c




¹⁹F NMR Spectrum of Compound 2c




¹H NMR Spectrum of Compound 2d




¹³C NMR Spectrum of Compound 2d




¹⁹F NMR Spectrum of Compound 2d




¹H NMR Spectrum of Compound 2e




¹³C NMR Spectrum of Compound 2e




^{19}F NMR Spectrum of Compound 2e




^1H NMR Spectrum of Compound 2f




¹³C NMR Spectrum of Compound 2f




¹⁹F NMR Spectrum of Compound 2f




¹H NMR (CDCl₃, 600MHz)




¹H NMR Spectrum of Compound 2g




¹³C NMR Spectrum of Compound 2g




¹⁹F NMR Spectrum of Compound 2g




¹H NMR Spectrum of Compound 2h




¹³C NMR Spectrum of Compound 2h




¹⁹F NMR Spectrum of Compound 2h




¹H NMR (CDCl₃, 400MHz)




¹H NMR Spectrum of Compound 2i




¹³C NMR (CDCl₃, 101MHz)




¹³C NMR Spectrum of Compound 2i




^{19}F NMR (CDCl_3 , 376MHz)




^{19}F NMR Spectrum of Compound 2i




^1H NMR (CDCl_3 , 400MHz)




^1H NMR Spectrum of Compound 2j




¹³C NMR Spectrum of Compound 2j




¹⁹F NMR Spectrum of Compound 2j




¹H NMR (CDCl₃, 600MHz)




¹H NMR Spectrum of Compound 2k




¹³C NMR (CDCl₃, 151MHz)




¹³C NMR Spectrum of Compound 2k



^{19}F NMR (CDCl₃, 565MHz)




^{19}F NMR Spectrum of Compound 2k




^1H NMR (CDCl₃, 600MHz)


^1H NMR Spectrum of Compound 2l




¹³C NMR Spectrum of Compound 2l




¹⁹F NMR Spectrum of Compound 2l




¹H NMR Spectrum of Compound 2m



¹³C NMR Spectrum of Compound 2m




^{19}F NMR (CDCl_3 , 376MHz)




^{19}F NMR Spectrum of Compound 2m


7.70, 7.68, 7.44, 7.43, 7.42, 7.41, 7.40, 7.38, 7.28, 7.26, 7.25, 7.10, 7.09, 6.99, 6.98, 4.88, 4.87, 4.86, 4.85, 4.52, 4.51, 4.50, 4.49, 4.41, 3.87, 3.85, 3.83, 3.33, 3.32, 3.31, 3.30, 3.29, 2.97, 2.96, 2.95, 2.94, 2.92, 2.92, 2.90, 2.89, 2.88, 2.87




^1H NMR (CDCl_3 , 600MHz)




^1H NMR Spectrum of Compound 2n




¹³C NMR Spectrum of Compound 2n




¹⁹F NMR Spectrum of Compound 2n




¹H NMR Spectrum of Compound 2o




¹³C NMR Spectrum of Compound 2o




¹⁹F NMR Spectrum of Compound 2o




¹H NMR Spectrum of Compound 2p




¹³C NMR Spectrum of Compound 2p




¹⁹F NMR Spectrum of Compound 2p




¹H NMR Spectrum of Compound 2q



¹³C NMR Spectrum of Compound 2q




^{19}F NMR (CDCl_3 , 376MHz)




^{19}F NMR Spectrum of Compound 2q




^1H NMR (CDCl_3 , 400MHz)




^1H NMR Spectrum of Compound 2r




¹³C NMR Spectrum of Compound 2r




¹⁹F NMR Spectrum of Compound 2r




¹H NMR Spectrum of Compound 2s




¹³C NMR Spectrum of Compound 2s




¹⁹F NMR Spectrum of Compound 2s




¹H NMR Spectrum of Compound 2t




¹³C NMR Spectrum of Compound 2t




¹⁹F NMR Spectrum of Compound 2t




¹H NMR Spectrum of Compound 2u




¹³C NMR Spectrum of Compound 2u



¹⁹F NMR (CDCl₃, 565MHz)




¹⁹F NMR Spectrum of Compound 2u




¹H NMR (DMSO, 600MHz)


¹H NMR Spectrum of Compound 2v




¹³C NMR Spectrum of Compound 2v




¹⁹F NMR Spectrum of Compound 2v




¹H NMR Spectrum of Compound 2w




¹³C NMR Spectrum of Compound 2w




¹⁹F NMR Spectrum of Compound 2w




¹H NMR Spectrum of Compound 2x




¹³C NMR Spectrum of Compound 2x




¹⁹F NMR Spectrum of Compound 2x




¹H NMR Spectrum of Compound 2y




¹³C NMR Spectrum of Compound 2y




¹⁹F NMR Spectrum of Compound 2y




¹H NMR Spectrum of Compound 2z




¹³C NMR Spectrum of Compound 2z




¹⁹F NMR Spectrum of Compound 2z




¹H NMR Spectrum of Compound 2aa




¹³C NMR Spectrum of Compound 2aa




¹⁹F NMR Spectrum of Compound 2aa




¹H NMR Spectrum of Compound 2ab




¹³C NMR Spectrum of Compound 2ab




¹⁹F NMR Spectrum of Compound 2ab




¹H NMR Spectrum of Compound 2ac





¹³C NMR Spectrum of Compound 2ac




¹⁹F NMR Spectrum of Compound 2ac




¹H NMR Spectrum of Compound 2ad







¹H NMR Spectrum of Compound 2ae




¹³C NMR Spectrum of Compound 2ae




¹⁹F NMR Spectrum of Compound 2ae




¹H NMR Spectrum of Compound 2af




^{13}C NMR (CDCl_3 , 101MHz)




^{13}C NMR Spectrum of Compound 2af




^{19}F NMR (CDCl_3 , 376MHz)




^{19}F NMR Spectrum of Compound 2af



¹H NMR (CDCl₃, 400MHz)




¹H NMR Spectrum of Compound 2ag




¹³C NMR (CDCl₃, 101MHz)


¹³C NMR Spectrum of Compound 2ag




^{19}F NMR (CDCl_3 , 376MHz)




^{19}F NMR Spectrum of Compound 2g




^1H NMR (CDCl_3 , 600MHz)



^1H NMR Spectrum of Compound 2ah



¹³C NMR Spectrum of Compound 2ah



¹⁹F NMR Spectrum of Compound 2ah